Gujarat Themis Biosyn Ltd (GUJTHEM) Stock Analysis: Valuation, Latest Results, Financial Ratios & DeciZen Rating

BSE: 506879 | NSE: GUJTHEM | Pharmaceuticals & Drugs | Small Cap

Guj. Themis Biosyn Share Price

377.65 -9.95 -2.57%
as on 05-Dec'25 16:59

Gujarat Themis Biosyn Ltd (GUJTHEM) Stock Analysis: Valuation, Latest Results, Financial Ratios & DeciZen Rating

BSE: 506879 | NSE: GUJTHEM | Pharmaceuticals & Drugs | Small Cap

DeciZen - make an informed investing decision on Guj. Themis Biosyn

Based on:

Overall Rating
Login to view analysis. Bole Toh

1. Quality


Login to view analysis.

2. Valuation


Login to view analysis.

3. Price Trend


Login to view analysis.

Gujarat Themis Biosyn stock performance -

Key Ratios
mw4me loader
P/E Ratio (SA):
85.21
Market Cap:
4,115.1 Cr.
52-wk low:
192.4
52-wk high:
479.5

Is Gujarat Themis Biosyn Ltd an attractive stock to invest in?


Login to view analysis.

10 Year X-Ray of Guj. Themis Biosyn: Login to view analysis.

Analysis of Financial Track Record

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end
Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end.

Financial track record gives insight into the company's performance on key parameters over the past ten years. MoneyWorks4me’s proprietary colour codes make it easy for retail investors to gauge the company’s past performance.
Gujarat Themis Biosyn Ltd has performed well in majority of the past ten years indicating its past ten year financial track record is very good

Value Creation

Value Creation Index Colour Code Guide

Mar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23Mar'24Mar'25TTM
ROCE % 80.4%54.7%42.2%44.9%86%67.9%67.9%61.5%45.4%27.5%-
Value Creation
Index
4.72.92.02.25.13.93.93.42.21.0-

Growth Parameters

Growth Parameters Colour Code Guide

Sales 32.635.738.841.185.190.6115148170151155
Sales YoY Gr.-9.4%8.7%5.8%107.4%6.4%26.8%29.2%14.4%-11.2%-
Adj EPS 0.40.40.40.62.22.845.35.44.54.4
YoY Gr.--7%-10%61.1%274.1%27.7%44.4%33%2.1%-17.7%-
BVPS (₹) 0.40.81.11.73.96.49.513.718.522.824.3
Adj Net
Profit
4.74.43.96.423.730.243.65859.248.748
Cash Flow from Ops. 3.92.85.60.70.610.540.339.564.291-
Debt/CF from Ops. 0.91.40.18.812.90.30000.3-

CAGR

CAGR Colour Code Guide

9 Years 5 Years 3 Years 1 Years
Sales 18.5%12.1%9.5%-11.2%
Adj EPS 29.7%15.6%3.8%-17.7%
BVPS59%42.6%34%23.3%
Share Price 46.2% 58.5% 53.4% 11%

Key Financial Parameters

Performance Ratio Colour Code Guide

Mar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23Mar'24Mar'25TTM
Return on
Equity %
305.172.538.141.67853.850.445.933.821.718.8
Op. Profit
Mgn %
18.71716.117.937.444.550.549.646.445.744.9
Net Profit
Mgn %
14.312.21015.527.833.33839.134.832.331.1
Debt to
Equity
0.90.50.10.30.200000.10.3
Working Cap
Days
5578739214420422626724522260
Cash Conv.
Cycle
-47-26-22-1927546247242828

Recent Performance Summary

Login to view analysis.
Login to view analysis.

Latest Financials - Gujarat Themis Biosyn Ltd.

Standalone Consolidated
TTM EPS (₹) 4.4 -
TTM Sales (₹ Cr.) 155 -
BVPS (₹.) 24.3 -
Reserves (₹ Cr.) 254 -
P/BV 15.56 -
PE 85.21 -
From the Market
52 Week Low / High (₹) 192.35 / 479.45
All Time Low / High (₹) 0.20 / 479.45
Market Cap (₹ Cr.) 4,115
Equity (₹ Cr.) 10.9
Face Value (₹) 1
Industry PE 40.6

Management X-Ray of Guj. Themis Biosyn:

Shareholding Pattern

Promoter's Holding & Share Pledging

Pledged *0.000.003.303.303.303.303.303.300.003.30
* Pledged shares as % of Promoter's holding (%)

Valuation of Guj. Themis Biosyn - Standalone Basis

YTD 1Y 3Y 5Y 10Y Max
mw4me loader

YTD 1Y 3Y 5Y 10Y Max
mw4me loader

YTD 1Y 3Y 5Y 10Y Max
mw4me loader

YTD 1Y 3Y 5Y 10Y Max
mw4me loader

mw4me loader

Event Update

Login/Register to view analysis.

Analyst's Notes

data not found
No data found!

Key Ratios of Guj. Themis Biosyn

Adj EPS (Rs.)

Sales (Cr.)

ROE (%)

ROCE (%)

Profit And Loss

(All Figures are in Crores.)
PARTICULARSMar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23Mar'24Mar'25
Sales333639418591115148170151
Operating Expenses 27303334535057759182
Manufacturing Costs21222426342631374043
Material Costs0121111516263623
Employee Cost 444567781011
Other Costs 1122223455
Operating Profit 6667324058747969
Operating Profit Margin (%) 18.5%16.9%16.1%17.9%37.4%44.5%50.5%49.6%46.4%45.7%
Other Income 0002234742
Interest 0000111000
Depreciation 1111122345
Exceptional Items 0000000000
Profit Before Tax 5558314159777966
Tax 011281115192017
Profit After Tax 5446243044585949
PAT Margin (%) 14.2%12.3%10.0%15.6%27.8%33.3%38.0%39.1%34.8%32.3%
Adjusted EPS (₹)0.40.40.40.62.22.84.05.35.44.5
Dividend Payout Ratio (%)0%0%0%0%10%0%37%14%12%15%

Balance Sheet

(All Figures are in Crores.)
PARTICULARSMar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23Mar'24Mar'25

Equity and Liabilities

Shareholders Fund 4812194270103149201248
Share Capital 77777777711
Reserves -31511356396142194237
Minority Interest0000000000
Debt12003000030
Long Term Debt11003000030
Short Term Debt0100000000
Trade Payables6766747101015
Others Liabilities 4439182527283025
Total Liabilities 152120337198137187241318

Fixed Assets

Gross Block42121318222628445159
Accumulated Depreciation32123579111318
Net Fixed Assets 9111115171919333841
CWIP 000102132191184
Investments 0000000000
Inventories010066121535
Trade Receivables2736201525182731
Cash Equivalents 0042228129813
Others Assets 2329252956927343
Total Assets 152120337198137187241318

Cash Flow

(All Figures are in Crores.)
PARTICULARSMar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23Mar'24Mar'25
Cash Flow From Operating Activity 436111140396491
PBT 5558314159777966
Adjustment 211-41-00-205
Changes in Working Capital -2-3-0-2-24-20-4-15437
Tax Paid -1-1-1-1-7-10-15-20-20-16
Cash Flow From Investing Activity -1-3-1-6-3-2-30-20-55-112
Capex -1-3-1-6-3-3-14-24-75-116
Net Investments -0000000000
Others 000001-163194
Cash Flow From Financing Activity -3-0-452-5-14-13-926
Net Proceeds from Shares 0000000000
Net Proceeds from Borrowing 00000000030
Interest Paid -0-0-0-0-0-0-0-0-0-0
Dividend Paid 00000-2-10-12-7-2
Others -30-452-2-4-1-2-1
Net Cash Flow -0010-03-4605

Finance Ratio

PARTICULARSMar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23Mar'24Mar'25
Ratios
ROE (%)302.7172.6338.0641.8577.9953.8250.3545.9233.7621.69
ROCE (%)80.3854.6742.2244.8885.9667.8967.9161.5145.427.48
Asset Turnover Ratio2.221.981.851.541.641.070.980.920.790.54
PAT to CFO Conversion(x)0.80.751.50.170.040.370.910.671.081.86
Working Capital Days
Receivable Days25474638567063534871
Inventory Days4554142428321910
Payable Days6,3321,5551,0801,96721513311511499193

Gujarat Themis Biosyn Ltd Stock News

Gujarat Themis Biosyn Ltd FAQs

The current trading price of Guj. Themis Biosyn on 05-Dec-2025 16:59 is ₹377.6.
Market capitalization or market cap is determined by multiplying the current market price of a company's shares with the total number of shares outstanding. As of 04-Dec-2025 the market cap of Guj. Themis Biosyn stood at ₹4,115.1.
The latest P/E ratio of Guj. Themis Biosyn as of 04-Dec-2025 is 85.21.
The latest P/B ratio of Guj. Themis Biosyn as of 04-Dec-2025 is 15.56.
The 52-week high of Guj. Themis Biosyn is ₹479.4 and the 52-week low is ₹192.3.
The TTM revenue is Trailing Twelve Months sales. The TTM revenue/sales of Guj. Themis Biosyn is ₹155.5 ( Cr.) .

About Gujarat Themis Biosyn Ltd

Gujarat Themis Biosyn Ltd, established in 1981, is a biotech and synthetic product manufacturing company, having plants at Vapi, Hyderabad, with group turnover of over $ 40 million. It has EDMFs, available and WHO approved plants.

The company has world-wide exports to satisfied customers, having customised facility for all products.

The company’s principal activity is to manufacture and distributes pharmaceuticals bulk drugs called rifampicin produced by fermentation process. The company's products include preparations of active pharmaceutical ingredient rifampicin and lovastatin. The company exports its products to Europe and the United States.

Kopran alongwith Cadila Healthcare Ltd., Lyka Labs Ltd., Themis Chemicals Ltd. and Anant & Co., formed Pharmaceutical Business Group (India) Ltd. in 1990.PBG acquired Gujarat Themis Biosyn Ltd (GTBL) as a sick company from BIFR in collaboration with Yuhan Corporation, South Korea and became India’s first producer of Rifampicin.Yuhan has provided technology for Rifampicin from fermentation and invested in equity also.

Business area of the company

  • Pharmaceuticals & Drugs
To get DeciZen Rating of 3,500+ Stocks based on their Quality, Valuation and Price Trend Login Now

© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×